DDL2020 Programme

Wednesday 9th December 2020

10:00 - 12:00

Conference Opens

  • Visit the Exhibition Booths & network with Exhibitors
  • View the On-Demand Presentations
  • Visit the Networking Lounge to network with other Attendees

 

12:00

Conference Lectures Begin

12:00 - 12:05

Welcome to the DDL2020 Christmas Lectures

Gary Pitcairn, DDL Chair

12:05 - 12:10

Introduction to Wednesday’s Presentations

Chair – Regina Scherließ

12:10 - 12:40

Surfactant Foam Therapy for Severe Covid-19 Patients with Acute Respiratory Distress Syndrome (ARDS)

Josué Sznitman, Department of Biomedical Engineering, Technion – Israel Institute of Technology, Israel

12:40 - 13:10

Environmental Impacts of Inhalers- a Cradle to Grave Review

Harish Jeswani, University of Manchester, UK

13:10 - 13:40

Presentation by DDL2020 Emerging Scientist Award Winner Jenny Lam

Selected from a pool of exceptional applicants, the DDL2020 Emerging Scientist Winner presents their research

13:40 - 13:50

How to design materials for inhalation devices to be more sustainable?

Beate Treffler, Avient Corporation formerly Clariant Masterbatches, Germany

13:50 - 14:00

The Application of Thermofluid Mechanic Modelling to the Development of Novel pMDI Devices 

Benjamin Thorne, University of Hertfordshire, UK

 

14:00 - 14:10

Systems Engineering Approaches to Device Development

Chris Hurlstone, Team Consulting, UK

 

14:10 - 14:40

BREAK

Free time to explore the Exhibition Hall, view the On-Demand presentations, catch up with colleagues in the Networking Lounge or grab a quick drink!

 

14:40 - 14:45

Introduction to the Interactive Discussion Forum

Hosted by the DDL New Researcher Network Committee

14:45 - 15:15

Discussion Forum Topic:

“Sustainability vs effective drug delivery to the lungs”

Experts:

Josué Sznitman, Israel Institute of Technology

Michelle Dawson, Pharmaron UK

Format:

The discussion forum will focus on the extent to which sustainability is compatible with drug delivery to the lungs and what needs to be taken into account in this context.

Join in: Attendees are invited to join in the discussion where you can pose your questions, ideas and thoughts to our experts.

Participate with video and text chat, or simply listen to the conversation live as it takes place.

15:15 - 16:15

Visit the Exhibition Booths & network with Exhibitors

View the On-Demand Presentations

Visit the Networking Lounge to network with other Attendees

 

16:15

Conference Closes

Thursday 10th December 2020

10:00 - 12:00

Conference Opens

  • Visit the Exhibition Booths & network with Exhibitors
  • View the On-Demand Presentations
  • Visit the Networking Lounge to network with other Attendees

 

12:00

Conference Lectures Begin

12:00 - 12:05

Introduction to Thursday’s Presentations

Chair – Ben Forbes

12:05 - 12:35

Powder Microstructural Analysis for Inhalation Blends

Darragh Murnane, University of Hertfordshire, UK

12:35 - 13:05

5-Azacytidine inhaled dry powder formulation profoundly improves pharmacokinetics and efficacy for lung cancer therapy through genome reprogramming

David Lyon, Lonza Pharma & Biotech, USA

 

13:05 - 13:15

Pseudomonas Phage Cocktail Powders for Respiratory Infections 

Mengyu Li, University of Sydney, Australia

13:15 - 13:25

Development of airways protection against respiratory Nipah virus infection by inhalation of antiviral peptides

Claire Dumont, University of Lyon, France

 

13:25 - 13:35

Engineering of inhalable microparticles containing terbinafine for management of pulmonary fungal infections

Khaled Fahad Almansour, University of Hail, Saudi Arabia

 

 

13:35 - 13:45

Development of Inhalable Powder Formulation of Broad-Spectrum Antiviral Agent   for Respiratory Viral Infections

Qiuying Liao, University of Hong Kong, Hong Kong

 

13:45 - 13:55

High dose antibiotic therapy – Sweeper crystals to enhance fine particle dose in the Twister device

Christian Etschmann, Kiel University, Germany

13:55 - 14:25

BREAK

Free time to explore the Exhibition Hall, view the On-Demand presentations, catch up with colleagues in the Networking Lounge or grab a quick drink!

14:25 - 14:30

Introduction to the Discussion Forum

Hosted by the DDL New Researcher Network Committee

14:30 - 15:00

Discussion Forum Topic:

“Formulation strategies to balance local drug delivery and systemic side effects”

Experts:

Ulrika Tehler, AstraZeneca

Rebecca Fransson, AstraZeneca

Format:  The discussion forum will focus on various formulation strategies which can help in balancing the local drug delivery and systemic side effects and what factors need to be taken into account when developing these formulations.

Join in: Attendees are invited to join in the discussion where you can pose your questions, ideas and thoughts to our experts.

Participate with video and text chat, or simply listen to the conversation live as it takes place.

15:00 - 16:15

Visit the Exhibition Booths & network with Exhibitors

View the On-Demand Presentations

Visit the Networking Lounge to network with other Attendees

16:15

Conference Closes

 

Friday 11th December 2020

10:00 - 12:00

Conference Opens

  • Visit the Exhibition Booths & network with Exhibitors
  • View the On-Demand Presentations
  • Visit the Networking Lounge to network with other Attendees

12:00

Conference Lectures Begin

 

12:00 - 12:05

Introduction to Friday’s Presentations

Chair – Nick Childerhouse

12:05 - 12:35

Data Science and AI in drug development– challenges and case studies from AstraZeneca

Anders Broo, AstraZeneca, Sweden

12:35 - 13:05

DIGITAL Inhalers – a panacea for respiratory patients?

Professor Sinthia Bosnic-Anticevich, University of Sydney, Australia

13:05 - 13:15

Improving dry powder inhaler performance: An integrated approach

Vishal Chaugule, Monash University, Australia

 

13:15 - 13:25

Impact of Layer Height on the Quality of DPI Prototypes Prepared by Masked Stereolithography 3D Printing

Kai Berkenfeld, University of Bonn, Germany

 

13:25 - 13:35

Konjac glucomannan microcarriers and macrophages – a promising interaction in lung diseases treatment

Filipa Guerreiro, University of Algarve, Portugal

13:35 - 13:45

Inhalable Microparticles Embedding Therapeutic CaP Nanoparticles for Heart Target

Eride Quarta, University of Parma, Italy

13:45 - 13:55

Benchmarking of particle engineering technologies for nasal powder manufacture

Patrícia Ferreira Dias Henriques,  Hovione and University of Coimbra, Portugal

 

13:55 - 14:25

BREAK

Free time to explore the Exhibition Hall, view On Demand presentations, catch up with colleagues in the Networking Lounge or grab a quick drink!

 

14:25 - 14:30

Introduction to the Discussion Forum

Hosted by the DDL New Researcher Network Committee

14:30 - 15:00

Discussion Forum Topic:

“Dry Powder technologies – Back to the future?”

Experts:

Lea Ann Dailey, University of Vienna

David Harris, Cambridge Healthcare Innovations

Format:  The discussion forum will focus on challenges and benefits around dry powder formulations, devices and patient compliance. What have we learnt so far and how it can be used in the future?

Join in: Attendees are invited to join in the discussion where you can pose your questions, ideas and thoughts to our experts.

Participate with video and text chat, or simply listen to the conversation live as it takes place.

15:00 - 16:00

Visit the Exhibition Booths & network with Exhibitors

View the On-Demand Presentations

Visit the Networking Lounge to network with other Attendees

16:00 - 16:10

Closing Remarks

Gary Pitcairn, DDL Chair

16:10

Conference Closes

 

On-Demand Presentations

No: 1

Laboratory Study to Evaluate a Pressurized Metered Dose Inhaler with Valved Holding Chamber (pMDI + VHC) Use Scenario in COVID-19 Situation where pMDIs in Short Supply

Jason Suggett, Trudell Medical International, Canada

No: 2

High-fidelity simulations of multi-component pressurised metered-dose inhaler sprays

Daniel Duke, Monash University, Australia

No: 3

PMDI leakage and ingress algorithm for new lower global warming propellants  

William Treneman, UPC Cambridge Limited, UK

 

No: 4

Predicting pMDI formulation thermophysical properties using activity coefficient models

Joseph Camm, Canterbury Christ Church University, UK

No: 5

A Dispersible Salbutamol Sulphate Tablet for an Environmentally Sustainable HFC 152a Propellant

Rachael Kay, i2cpharma Services, UK & Ségolène Sarrailh, Aptar Pharma, France

 

No: 6

Novel Flow Sensor and Electronic Platform for Smart Metered-Dose Inhalers

Haykel Ben Jamaa, Sensirion, Switzerland

No: 7

Exploring the potential and practicalities of semi-automation in inhaler testing

Raquel Borda D’Agua, Hovione FarmaCiencia S.A.,Portugal & Anna Sipitanou, Copley Scientific Ltd, UK

No: 8

Indian generic fluticasone/salmeterol dry powder inhalers – An aerodynamic comparison

Waiting Tai, University of Sydney, Australia

No: 9

In vitro comparison of Indian generic fluticasone/salmeterol metered dose inhalers

Tsz Hei Kwong, University of Sydney, Australia

No: 10

In-Vitro Study of Inhaled Iloprost Delivery Using a Modified Deepro Mesh Nebulizer with Breath-Actuated Function  

Edgar Hernan Cuevas Brun, HCmed Innovations Co. Ltd, Taiwan

No: 11

New in-vitro bioequivalence approaches for generic nasal suspension products

Ethan Dixon-Naish, Intertek Melbourn

No: 12

The relevance of simulated lung fluid composition on the drug solubility and predicted in-vivo performance of inhaled drug delivery

Snezana Radivojev, University of Graz, Austria

No: 13

Comparative Assessment of Pharmacokinetics and Acute Lung Inflammation of Nicotine Dry Powder Aerosols Generated by PreciseInhale®

Sharon Lam, Philip Morris International Research Laboratories Pte Ltd, Singapore

No: 14

In silico and in vitro aerodynamic profile of chitosan/thiolated chitosan and hyaluronic acid hybrid nanoplex based DPIs for tuberculosis

Mahwash Mukhtar, University of Szeged, Hungary

No: 15

Spray-dried composite formulation for lung sustained release

Beatriz Noriega Fernandes, Hovione FarmaCiência SA, Portugal

No: 16

Dry Powder Inhaler for lung to heart drug delivery

Gildas Huet & Raphaële Audibert, Nemera, France

No: 17

Integrated Acoustic Actuator for Signalling Inhaler Activity

Mark Sanders, Clement Clarke International Limited, UK

No: 18

Carbon footprint assessment of Breezhaler® dry powder inhaler

Simon Aumonier, ERM, UK

 

No: 19

To Connect, or, Not to Connect

Paul Greenhalgh, Team Consulting, UK

No: 20

The impact of emerging European Commission sustainability policy on respiratory inhaler development

Sarah Wren, PA Consulting, UK

No: 21

Computational fluid dynamics simulation of cavitating propellant flow inside a pressurised metered dose inhaler expansion chamber, using volume of fluid method

Barzin Gavtash, Kindeva Drug Delivery Limited, UK

No: 22

The path to a sustainable future for inhalation products

Dan Cowen, Cambridge Consultants Ltd, UK

No: 23

Computational analysis of helical aerosol streams for controlled micro- or nano-drug delivery in representative human upper lung airways

Adithya Gurumurthy, North Carolina State University, United States

No: 24

Exploring In Vitro Equivalence Tests Using a Bayesian Hierarchical Model

William J Ganley, Nanopharm Ltd, an Aptar Pharma Company, UK

No: 25

The attitude of UK asthma patients towards ‘smart’ and connected inhaler features

Matt Jones, DCA Design International Ltd, UK

No: 26

Development of chrysin dry powder inhaler formulation for the potential treatment of respiratory-related diseases

Rahaf Oum, University of Bradford, UK

No: 27

Methionine offers superior aerosolization stability over leucine for inhalable high-dose spray-dried kanamycin formulation

Bishal Raj Adhikari, University of Otago,  New Zealand

No: 28

Comparing the Aerosol In Vitro Performance and Surface Energetics of Dry Powder Inhaler Formulations

Abdullateef J. Jamal, University of Bradford, UK

No: 29

Influence of the opening size on the air velocity through the capsule in the capsule based DPI’s

Milica Stankovic-Brandl, Research Center Pharmaceutical Engineering, Austria

No: 30

Optimising DPI formulations – The influence of surface energy on the suitability of additional fines

Nicholas Bungert, Kiel University, Germany

No: 31

Probing the effect of USP induction port geometry on aerodynamic performance of dry powder inhalers

Piyush Pradeep Mehta, Bharati Vidyapeeth Deemed to be University, India

No: 32

Solid state modification of ciprofloxacin for high dose dry powder inhalation

Thomas Hibbard, University of Reading, UK

No: 33

The Influence of blend composition on the aerodynamic performance of a novel high resistance multi-dose device

Irene Rossi, Nanopharm Ltd, An Aptar Pharma Company, UK

No: 34

Development of NSAID-containing dry powder inhalation formulation co-spray-dried with sodium stearate

Edit Benke, University of  Szeged, Hungary

No: 35

In Vitro Performance of the Handihaler and the Respimat Soft Mist Inhaler Under Inhalation Profiles Simulating COPD

Janelle Soong, King’s College, London, UK

No: 36

Efficacy of the PARI Filter/Valve set to prevent environmental contamination with aerosol during nebulizer therapy

Uwe Schuschnig, PARI GmbH, Germany

No: 37

Formulation and characterization of spray-dried budesonide in organic solvent suspensions for aerosol delivery to the lungs

Wei-Ren Ke, University of Sydney, Australia

No: 38

Use of A Sectional Adult Nasal Airway Model for the Evaluation of Nasal Delivery Devices and Administration Techniques

Mark W Nagel, Trudell Medical International, Canada

 

No: 40

Fucoidan-coated lipid nanocapsules encapsulating a model drug for lung drug delivery

Jorge F. Pontes, Universidade do Algarve, Portugal

No: 41

4 steps to selecting the ‘right’ delivery device for your inhaled therapy

Charlotte Harris, Team Consulting, UK

 

No: 42

30 years of Extractables and Leachables (E&L) in Inhalation Products, a rapid(s) ride

Jason Creasey, Maven E&L Ltd ,UK

No: 43

In silico modelling of regional lung deposition for metered dose and soft mist inhalers

Andy Cooper, Kindeva Drug Delivery Limited, UK

No: 44

Increased Sustainability Via the Use of Abbreviated Impactor Measurements (AIM) for Aerodynamic Particle Size Distribution (APSD) of Oral Pressurised Metered Dose Inhalers (pMDIs)

Jim Clay, Kindeva Drug Delivery Limited, UK

 

No: 45

Quantification of Surface Composition and Distribution of Inhalation Powders using TOF-SIMS

Mark Nicholas, AstraZeneca, Sweden

 

No: 46

Pressure and temperature measurements of current and future low GWP pMDI propellants in the actuator sump

Ben Myatt, Kindeva Drug Delivery UK

No: 47

Plume temperatures of current and future low GWP pMDI propellants measured in an anatomical throat geometry

Ben Myatt, Kindeva Drug Delivery UK

No: 48

Challenging the Challenges Of Nanoparticle Testing Using In Vitro Methods

Nashwa Osman, Liverpool John Moores University, UK